T 1351/23 (Blinatumomab/AMGEN) of 14.07.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T135123.20250714
- Date of decision
- 14 July 2025
- Case number
- T 1351/23
- Online on
- 12 September 2025
- Petition for review of
- -
- Application number
- 17159560.6
- IPC class
- C07K 16/28A61K 31/573A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS
- Applicant name
- Amgen Research (Munich) GmbH
- Opponent name
- James Poole Limited
F. Hoffmann-La Roche AG - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111European Patent Convention Art 84Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 012(6)
- Keywords
- Carry-over requests - admitted (yes)
Clarity (yes)
Remittal (yes) - Catchword
- -
- Cited cases
- G 0001/24
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution.